AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile Life Science Investing
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm Sublingual Film Pharmaceutical Investing
Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF Life Science Investing
Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027 Life Science Investing
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 Life Science Investing
NRx Pharmaceuticals, Inc. to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans Life Science Investing
AVITA Medical Announces Participation at Canaccord Genuity Growth Conference Medical Device Investing
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates Pharmaceutical Investing
